Skye Bioscience (NASDAQ: SKYE) recently received a number of ratings updates from brokerages and research firms:
- 9/20/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $20.00 price target on the stock.
- 9/20/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
- 9/10/2024 – Skye Bioscience is now covered by analysts at JMP Securities. They set an “outperform” rating and a $15.00 price target on the stock.
- 9/6/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
- 8/27/2024 – Skye Bioscience had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
Skye Bioscience Trading Down 5.1 %
Shares of SKYE traded down $0.20 during mid-day trading on Friday, reaching $3.76. 152,010 shares of the company’s stock traded hands, compared to its average volume of 167,080. Skye Bioscience, Inc. has a 12 month low of $1.44 and a 12 month high of $19.41. The stock’s 50-day moving average is $5.58 and its two-hundred day moving average is $5.98.
Skye Bioscience (NASDAQ:SKYE – Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). On average, equities analysts forecast that Skye Bioscience, Inc. will post -1.06 EPS for the current year.
Insider Buying and Selling at Skye Bioscience
Institutional Trading of Skye Bioscience
A number of hedge funds have recently bought and sold shares of the company. Cubist Systematic Strategies LLC acquired a new position in Skye Bioscience during the 2nd quarter valued at $30,000. Point72 DIFC Ltd acquired a new stake in Skye Bioscience during the second quarter worth $48,000. Rhumbline Advisers bought a new stake in Skye Bioscience in the 2nd quarter valued at $158,000. AdvisorShares Investments LLC bought a new position in shares of Skye Bioscience during the 2nd quarter worth about $210,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Skye Bioscience in the 2nd quarter worth approximately $222,000. 21.09% of the stock is owned by hedge funds and other institutional investors.
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Further Reading
- Five stocks we like better than Skye Bioscience
- What Are Dividend Champions? How to Invest in the Champions
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Stock Market Upgrades: What Are They?
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- Election Stocks: How Elections Affect the Stock Market
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Skye Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.